A Drug-Drug Interaction Study of Ketoconazole, Rifampicin and Ritonavir-Boosted Atazanavir With Single-Dose RO5093151 in Healthy Volunteers

Inclusion Criteria: * Healthy male and female subjects, 18 to 65 years of age. Healthy status is defined by absence of evidence of any active or chronic disease following a detailed medical and surgical history and complete physical examination * Body mass index (BMI) 18 to 30 kg/m2 * Females of child-bearing potential must agree to use two effective methods of contraception, including a barrier method and an intrauterine non-hormonal device (set in place at least 3 months before first dosing) for the duration of the study and at least 1 month after last dosing * Non-smoker for at least 90 days prior to screening Exclusion Criteria: * Pregnant or lactating females * History of drug abuse in the past 2 years, or suspicion of regular consumption of drugs of abuse, or positive result on drugs of abuse test * History of alcoholism in the past 2 years, or positive alcohol test * Positive for hepatitis B, hepatitis C or HIV infection * Systemic , topical, intranasal or inhaled corticosteroid therapy for more than 2 weeks within 3 months prior to screening * Participation in an investigational drug or device study within 90 days prior to screening